Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

5,075

Participants

Timeline

Start Date

May 1, 2006

Primary Completion Date

January 1, 2007

Study Completion Date

July 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Adjuvanted pandemic influenza candidate vaccine

2 doses, intramuscular injection

BIOLOGICAL

Fluarix

One intramuscular injection

BIOLOGICAL

Placebo

One intramuscular injection

Trial Locations (40)

10117

GSK Investigational Site, Berlin

10617

GSK Investigational Site, Tallinn

10787

GSK Investigational Site, Berlin

14052

GSK Investigational Site, Caen

14057

GSK Investigational Site, Berlin

17140

GSK Investigational Site, Lagord

19055

GSK Investigational Site, Schwerin

20249

GSK Investigational Site, Hamburg

22143

GSK Investigational Site, Hamburg

28006

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

GSK Investigational Site, Marid

28041

GSK Investigational Site, Madrid

30519

GSK Investigational Site, Hanover

44093

GSK Investigational Site, Nantes

46014

GSK Investigational Site, Valencia

46017

GSK Investigational Site, Valencia

50417

GSK Investigational Site, Tartu

58455

GSK Investigational Site, Witten

75877

GSK Investigational Site, Paris

76100

GSK Investigational Site, Rouen

80799

GSK Investigational Site, Munich

81667

GSK Investigational Site, Munich

86000

GSK Investigational Site, Poitiers

93053

GSK Investigational Site, Regensburg

97070

GSK Investigational Site, Würzburg

420015

GSK Investigational Site, Kazan'

620028

GSK Investigational Site, Yekaterinburg

620078

GSK Investigational Site, Yekaterinburg

654063

GSK Investigational Site, Novokuznetsk

01067

GSK Investigational Site, Dresden

04103

GSK Investigational Site, Leipzig

04229

GSK Investigational Site, Leipzig

3011 EN

GSK Investigational Site, Rotterdam

3015 GE

GSK Investigational Site, Rotterdam

Unknown

GSK Investigational Site, Saratov

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

SE-631 88

GSK Investigational Site, Eskilstuna

SE-141 86

GSK Investigational Site, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY